focus -WSS

focus

author：knowledge 2025-10-02 18:48:54 - browse：6

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Use wet bulb globe temperature, not heat index, to protect workers

focus

WSS

New chief aims to remake Sanofi Genzyme

After gene therapy, two congenitally deaf children hear for the first time

Biden White House, tech companies launch new safeguards around emerging AI technology

Reframing the conversation around gain

Reframing the conversation around gain

Apple Watch's A

knowledge

focus

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Prosecutors say FTX founder Sam Bankman

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Drug repurposing or repositioning? The language matters

First recipient of genetically engineered pig kidney has died

Moonlake's readout produced a cash windfall. Risks remain

Why Marc Tessier

DIEP, the 'gold standard' of breast reconstruction, is under threat

EMA weighs against approval for Mirati's lung cancer drug

focus

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Steward Health Care files for bankruptcy

Reframing the conversation around gain

Brain worms: The science behind RFK Jr.'s parasitic infection

Reframing the conversation around gain

What is artificial intelligence? Experts weigh in

hotspot

hotspot

focus

Wikipedia